GAITHERSBURG, Md.--(BUSINESS WIRE)--Calibrant Biosystems today announced a research collaboration with the Cleveland Clinic to identify novel drug targets for primary brain cancer using Calibrant’s Gemini proteomics platform. As part of the partnership, Calibrant will identify protein networks and novel therapeutic targets involved in the progression of the most common and aggressive primary brain cancer, glioblastoma multiforme (GBM).
